Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 03 2021 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company
dedicated to the development of cellular therapies designed to
reverse disease, announces that management will present a company
overview and hold virtual investor meetings at the H.C. Wainwright
Global Life Sciences Virtual Conference being held March 9-10,
2021.
If you are an institutional investor, and would like to listen
to the Company’s presentation, please click on the following link
(www.hcwevents.com/globalconference ) to register for the
conference. Over 400 corporate presentations & panels are
available Live and on-demand during March 9-10, 2021, starting on
March 9 at 7:00 A.M. (EST).
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study in the U.S. for the treatment of
coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12),
recipient of SAKIGAKE designation and eligible for early
conditional approval in Japan for the treatment of critical limb
ischemia (“CLI”) and Buerger’s Disease based on the results of an
ongoing clinical trial; CLBS201, designed to assess the safety and
efficacy of CD34+ cell therapy as a treatment for chronic kidney
disease (“CKD”) and OLOGO™ (CLBS14), a Regenerative Medicine
Advanced Therapy (“RMAT”) designated therapy for which the Company
is in discussion with the U.S. Food and Drug Administration (the
“FDA”) to finalize a Phase 3 protocol of reduced size and scope for
a confirmatory trial in subjects with no-option refractory
disabling angina (“NORDA”). For more information on the
Company, please visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone:
+1-908-842-0084Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024